Nicholas Ashton

Gothenburg

Neuroscientist in Dementia / Banner Health 🇺🇸/ University of Gothenburg 🇸🇪

Featured in: Favicon

nature.com Favicon

wiley.com

mdpi.com

springer.com Favicon

biomedcentral.com Favicon

jamanetwork.com Favicon

science.org Favicon

thelancet.com Favicon

neurology.org (+1) Favicon

neurologylive.com + 6 more

Articles

Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window

1 month ago | alz-journals.onlinelibrary.wiley.com | Yara Yakoub |Fernando Gonzalez-Ortiz |Nicholas Ashton |Christine Déry

1 BACKGROUND The core pathological hallmarks that define Alzheimer's disease (AD) are plaque-forming aggregates of amyloid beta (Aβ) and neurofibrillary tangles of hyper-phosphorylated tau (p-tau).
A blood test for Alzheimer’s disease: a decade of progress and success

Jan 6, 2025 | thelancet.com | Nicholas Ashton |SUN CITY

In 2014, when eBioMedicine launched its first issue, in vivo biomarkers to detect the hallmarks of Alzheimer’s disease (AD) were entirely restricted to position emission tomography (PET) and cerebrospinal fluid (CSF). There was certainly limited enthusiasm that a comparable determination about AD pathology or neurodegeneration could be made from an easily accessible biofluid such as blood.
Sex differences in the relationships between 24-h rest-activity patterns and plasma markers of Alzheimer’s disease pathology - Alzheimer's Research & Therapy

Dec 30, 2024 | alzres.biomedcentral.com | Maxime Van Egroo |Elise Beckers |Nicholas Ashton |Kaj Blennow |Henrik Zetterberg

ReferencesVan Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, et al. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease. Sleep. 2019;42:1–13. Google Scholar Rigat L, Ouk K, Kramer A, Priller J. Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer’s disease. Acta Physiol. 2023;238:1–13. Google Scholar Winer JR, Morehouse A, Fenton L, Harrison TM, Ayangma L, Reed M, et al.
Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer’s disease - Alzheimer's Research & Therapy

Dec 23, 2024 | alzres.biomedcentral.com | Georgette Argiris |Muge Akinci |Cleofé Peña-Gómez |Eleni Palpatzis |Marina García-Prat |Mahnaz Shekari | +8 more

ReferencesJack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Article PubMed Google Scholar Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.
Regulatory Standard for Determining Preoperative Skin Preparation Efficacy Underreports True Dermal Bioburden in a Porcine Model

Nov 20, 2024 | mdpi.com | Hannah Duffy |Nicholas Ashton |Abbey Blair |Nathanael Hooper

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Alzheimer's disease-Biomarkers, clinical evaluation or both?

Nov 14, 2024 | bpspsychub.onlinelibrary.wiley.com | Joel Simrén |Nicholas Ashton |Marc Suárez-Calvet |Henrik Zetterberg

Recent developments in fluid and imaging biomarkers that reflect the key pathological hallmarks of Alzheimer's disease (AD)—deposits of extracellular amyloid-β (Aβ) and intracellular tau proteins—have transformed the perception of the disease in living individuals from a clinical syndrome to a biological continuum that begins prior to the onset of symptoms (Scheltens et al., 2021).
Circulating medium‐ and long‐chain acylcarnitines are associated with plasma P‐tau181 in cognitively normal older adults

Oct 30, 2024 | onlinelibrary.wiley.com | Pratishtha Chatterjee |James D. Doecke |Nicholas Ashton |Tahmida Sharmin

1 INTRODUCTION Given a multifactorial disorder, Alzheimer's disease (AD) pathogenesis involves dysregulation in diverse biochemical processes (Dorszewska et al., 2016; Koutsodendris et al., 2022; López-Ortiz et al., 2021), including abnormal amyloid-β (Aβ) production and impaired Aβ clearance, tau hyperphosphorylation, insufficiency in brain glucose utilisation, mitochondrial dysfunction, lipid dyshomeostasis, oxidative stress, neuroinflammation and neurotransmitter dyshomeostasis (Toledo et...
A head-to-head comparison of plasma biomarkers to detect biologically defined Alzheimer in a memory clinic

Oct 27, 2024 | medrxiv.org | Federica Anastasi |Aida Fernández-Lebrero |Nicholas Ashton |Paula Ortiz-Romero

AS, QH and BZ are employees of Alamar Biosciencies, Inc. NLB and AN are employees of Fujirebio Europe N.V. and Fujirebio Iberia, respectively. TM is an employee of Meso Scale Diagnostics, LLC. GK is a full-time employee of Roche Diagnostics GmbH. MC is a full-time employee of Roche Diagnostics International Ltd and an owner of shares in Roche.
Alternating Magnetic Fields AMF) and Linezolid Reduce Staphylococcus aureus Biofilm in a Large Animal Implant Model

Sep 13, 2024 | journalofinfection.com | Isuru A Somawardana |Connor Hunt |Jacob Adams |Tyler Smith |Nicholas Ashton |John Tepper | +10 more

AbbreviationsPJI (Prosthetic joint infections)AMF (Alternating Magnetic Fields)S.
The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study

Aug 22, 2024 | medrxiv.org | Nicholas Ashton |Ashvini Keshavan |Wagner S. Brum |Ulf Andreasson

All biomarker measurements were performed by the assay developers in-house without cost. ALZpath p-tau217 was performed at the University of Gothenburg (UGOT) and Lilly immunoassays were performed at the University of Lund. C2N Diagnostics declined to participate in the study. N.J.A. has given lectures in symposia sponsored by Eli-Lilly, Roche Diagnostics, and Quanterix. NJA has declined paid opportunities from ALZpath. A.K. has no conflicts of interest. W.S.B. has no conflicts of interest.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 2K
Tweets: 3K
DMs Open: Yes

Nicholas Ashton @NicholasAshton

18 Apr 25

Our comments on the new #blood tests for #Alzheimers #disease which are increasingly improving and becoming applicable to clinical use. We should use them but use them in the correct way. https://t.co/fmxJGPu2Zb

Nicholas Ashton @NicholasAshton

9 Apr 25

RT @M_SuarezCalvet: 📢Our latest study, now published in @NatureMedicine , explores the potential of blood biomarkers on an automated platfo…

Nicholas Ashton @NicholasAshton

9 Apr 25

RT @biofinder_study: New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’…

Nicholas Ashton

Articles

Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window

A blood test for Alzheimer’s disease: a decade of progress and success

Sex differences in the relationships between 24-h rest-activity patterns and plasma markers of Alzheimer’s disease pathology - Alzheimer's Research & Therapy

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer’s disease - Alzheimer's Research & Therapy

Regulatory Standard for Determining Preoperative Skin Preparation Efficacy Underreports True Dermal Bioburden in a Porcine Model

Alzheimer's disease-Biomarkers, clinical evaluation or both?

Circulating medium‐ and long‐chain acylcarnitines are associated with plasma P‐tau181 in cognitively normal older adults

A head-to-head comparison of plasma biomarkers to detect biologically defined Alzheimer in a memory clinic

Alternating Magnetic Fields AMF) and Linezolid Reduce Staphylococcus aureus Biofilm in a Large Animal Implant Model

The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study

Contact details

Emails

Socials & Sites

X (formerly Twitter)